New Study Highlights XHANCE’s Efficacy in Treating Chronic Rhinosinusitis

Optinose

YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced the publication of a paper in the International Forum of Allergy & Rhinology, shedding light on the effectiveness of EDS-FLU (XHANCE) in treating patients with chronic rhinosinusitis (CRS) with or without prior sinus surgery. This peer-reviewed study analyzed data from two randomized controlled trials, ReOpen1 and ReOpen2, offering valuable insights for healthcare professionals dealing with CRS.

Chronic rhinosinusitis, particularly the variant without nasal polyps, often presents treatment challenges. Traditional topical medications struggle to reach the sinus cavities, limiting their effectiveness. Unlike rhinitis or nasal polyps, which are more responsive to standard nasal sprays, CRS requires a targeted approach. Endoscopic sinus surgery (ESS) is typically employed to facilitate medication delivery to the sinuses, but the role of prior surgery in treatment efficacy was unclear until now.

The Exhalation Delivery System™ with fluticasone (EDS-FLU; XHANCE) introduces a novel delivery mechanism that enhances the deposition of corticosteroids into the sinuses and drainage pathways. The study aimed to determine if this approach differed in effectiveness between patients with previously operated sinuses and those without surgery.

Results from the ReOpen1 and ReOpen2 trials, both spanning 24 weeks, revealed that XHANCE significantly improved symptoms, sinus opacification, and quality of life for CRS patients, regardless of their surgical history. This indicates that prior sinus surgery is not a prerequisite for experiencing the benefits of XHANCE, making it a versatile treatment option for healthcare providers.

This research spotlights the potential of XHANCE to enhance the management of chronic rhinosinusitis, providing a promising solution for patients who have undergone surgery and those who have not. Healthcare professionals can now consider XHANCE as a viable treatment option, broadening the possibilities for effectively managing this complex condition.

READ:  Savara Inc. Shines Spotlight on Rare Lung Disease in New TV Feature

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.